<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00096798</url>
  </required_header>
  <id_info>
    <org_study_id>K23AT001129</org_study_id>
    <nct_id>NCT00096798</nct_id>
  </id_info>
  <brief_title>Ethyl Eicosapentanoic Acid (Ethyl-EPA) for Treating Major Depression</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Study of Ethyl Eicosapentanoic Acid (Ethyl-EPA) in Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Center for Complementary and Integrative Health (NCCIH)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effectiveness of ethyl-eicosapentanoic acid
      (ethyl-EPA), an omega-3 fatty acid, in treating depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evidence suggests that omega-3 fatty acids may help reduce symptoms of depression. This study
      will determine whether ethyl-EPA, an omega-3 fatty acid, can be used safely and effectively
      to treat major depression.

      Participants will be randomly assigned to receive either ethyl EPA-containing pills or
      placebo daily for 8 weeks. Each week, participants will be asked to complete questionnaires
      which will be used to assess the severity of their depression.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2001</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alleviation of depressive symptoms</measure>
  </primary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Depressive Disorder</condition>
  <condition>Depression</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethyl-eicosapentanoic acid (ethyl-EPA)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Major depressive disorder

        Exclusion Criteria:

          -  Serious comorbid psychiatric disorder

          -  Unstable medical illness

          -  Prior use of any omega-3 fatty acid product
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Mischoulon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2004</study_first_submitted>
  <study_first_submitted_qc>November 15, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2004</study_first_posted>
  <last_update_submitted>January 15, 2008</last_update_submitted>
  <last_update_submitted_qc>January 15, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2008</last_update_posted>
  <keyword>Fatty Acids, Omega-3</keyword>
  <keyword>Antidepressive Agents</keyword>
  <keyword>Eicosapentanoic Acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

